Smoking Cessation and Nicotine De-addiction Market by Products (Nicotine Replacement Therapy [Nicotine Spray, Nicotine Inhalers, Nicotine Gum, Nicotine Transdermal Patches, Nicotine Sublingual Tablets, and Nicotine Lozenges], Drug Therapy [Varenicline, Zyban, and Nicorette Buccal], and E-cigarettes/E-liquid) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028.

The global smoking cessation and nicotine de-addiction market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the high prevalence of diseases such as cardiac diseases, respiratory disorders, and lung cancer caused due to rising smoking habits among a large number of adults globally.

Nicotine de-addiction or smoking cessation involves adoption of various means or methods to stop tobacco consumption and reduce its addiction. Tobacco consists of nicotine, which is responsible for developing into addiction due to the neurotransmitters such as dopamine, glutamate, and gamma-aminobutyric acid (GABA). The products related to smoking cessation are used to stop cigarette and tobacco addicts. The market for nicotine de-addiction and smoking cessation products includes electronic cigarettes, nicotine replacement therapy (NRT), along with therapeutic drugs such as nicotine receptor agonists and anti-depressants. Several government have released policies to regulate the nicotine quantity and cigarette products to reduce the addiction as it has toxic effects on respiratory systems and heart. The government regulations on smoking cessation are increased through taxation on tobacco products, advertisements for smoking prevention and awareness, ban of smoking in public places, and provision for smoking discontinuation therapies.

The diseases or health issues related to the smoking is highly prevalent in the world as large population are addicted to smoking or tobacco consumption. As per the Center for Diseases Control and Prevention (CDC), globally tobacco causes greater than 7 million deaths every year and if this trend continues, approximately 8 million people is estimated to die due to tobacco by 2030. The same report suggests about the death of 480000 people are occurred due to tobacco in the USA alone every year, which is around one in five deaths yearly. Smoking causes several diseases such as heart disease, cancer, diabetes, lung diseases, stroke, and chronic obstructive pulmonary disease (COPD).

Market Trends, Drivers, Restraints, and Opportunities

• Rising awareness about the smoking related diseases as well as high government initiatives for smoking prevention are driving the market expansion at a quick pace.
• High population of smoking people and increased chronic diseases due to smoking are encouraging people to quit smoking. These are key factors for boosting the market.
• Development of novel products for smoking and nicotine cessation is increasing the market revenue.
• Person’s unwillingness to accept the treatment and lack of awareness regarding the treatments are major challenges that can restrain the overall market growth.
• Increasing number of health-conscious population and governments’ policies towards tobacco cessation are huge opportunities for the market development in the near future.

Scope of the Report

The report on the global smoking cessation and nicotine de-addiction market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Nicotine replacement therapy segment is expected to grow at a rapid pace

Based on products, the global smoking cessation and nicotine de-addiction market is divided into nicotine replacement therapy, e-cigarettes, and drug therapy. The nicotine replacement therapy segment is further classified as nicotine spray, nicotine gum, nicotine inhalers, nicotine sublingual tablets, nicotine transdermal patches, and nicotine lozenges. The drug therapy segment is sub-segmented into varenicline, nicorette buccal, and zyban. The nicotine replacement therapy segment is expected to grow at a rapid pace during the forecast period owing to the factors such as easy availability, ease of use, and highly effective.

The drug therapy segment, however, is expected to grow at a significant pace in the coming years attributed to the use of excessive consumption of tobacco and wide cases of withdrawal symptoms that occur when the addicted person immediately stops the use of tobacco. The varenicline drug is recommended highly as it shows good effect in smoking cessation person. It is a non-nicotine based drug and marketed as champixin in the world and as chantix in the US. Zyban is also used on large scale with combination of nicotine replacement therapy. Meanwhile, the e-cigarettes segment is growing at a fast pace as it is gaining popularity around the globe. The rechargeable feature in the product is encouraging the people to use and, hence, getting good market response.

North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the projected period owing to the large number of targeted population and highly active awareness programs introduced by governments in the region. Additionally, good research activities in the field and significant awareness in the region are key factors propelling the market of the region.

The Asia Pacific market, however, is expected to expand at a substantial growth rate due to the presence of high number of unmet population, high economic growth, and the presence of huge target population. Moreover, increased government interest in the smoking cessation and beneficial policies are contributing to the market development during the forecast period. The World Health Organization launched ‘national smoke-free law’ in year 2015, in Asia Pacific to encourage people to quit smoking.

Segments

Segments Covered in the Report

The global smoking cessation and nicotine de-addiction market has been segmented on the basis of

Products

• Nicotine Replacement Therapy 
  • Nicotine Spray
  • Nicotine Inhalers
  • Nicotine Gum
  • Nicotine Transdermal Patches
  • Nicotine Sublingual Tablets
  • Nicotine Lozenges
• Drug Therapy
  • Varenicline
  • Zyban
  • Nicorette Buccal
• E-cigarettes/E-liquid

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Pfizer, Inc.
• Cipla Ltd.
• Novartis International AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Ltd.
• McNeil AB
• Revolymer plc
• Imperial Tobacco Ltd.
• VMR Products, LLC.

Competitive Landscape

The key players of the global smoking cessation and nicotine de-addiction market are Pfizer, Inc.; GlaxoSmithKline plc; Novartis International AG; Takeda Pharmaceutical Company Ltd.; Cipla Ltd.; McNeil AB; Revolymer plc; Imperial Tobacco Ltd.; and VMR Products, LLC.
Lorillard, Inc.; VMR products, LLC; NJOY; and Vapor Corp. are some of the major e-cigarettes producing companies. New product named as QuickMist, which was launched by Mcneil in 2015. The product was designed as a fast acting spray of nicotine that could act as an alternative for smoking.